ArticleOncoimmunology
Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 83 citations in OpenAlex.
- KLRB1 gene in tumor immune regulation and disease prognosis: a multidimensional role review.Discover oncology · 2026Review
- Advances in the molecular mechanisms and clinical applications of LEMD1 in tumor development and progression (Review).Molecular and clinical oncology · 2026Review
- Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours.Andrology · 2026Article
- Multi-omics highlights the impacts of cryptorchidism history on immune microenvironment variation in TGCT.Discover oncology · 2025Article
- Disparate Roles of Cell-Cell Contact and Cytokine Secretion in an In Vitro Model of the Seminoma Microenvironment.International journal of molecular sciences · 2025Article
- The clinical significance of T cell infiltration and immune checkpoint expression in central nervous system germ cell tumors.Frontiers in immunology · 2025Article
- Article
- Immune profiling of pediatric germ cell tumors identifies key cell populations and novel therapeutic targets.Frontiers in immunology · 2025Article
- Teratoma Development in 129.MOLF-Chr19 Mice Elicits Two Waves of Immune Cell Infiltration.International journal of molecular sciences · 2024Article
- The expression of programmed cell death ligand 1 (PD-L1) involves in the clinicopathologic characteristics and prognostic implications of testicular germ cell tumor (TGCT): a systematic review and meta-analysis.Translational cancer research · 2024Article
- T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets.British journal of cancer · 2024Article
- The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors.Cancers · 2024Review
- Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.International journal of molecular sciences · 2023Review
- Identification of testicular cancer immune infiltrates and novel immune cell subtypes.FEBS open bio · 2023Article
- TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- The Subtype Identity of Testicular Cancer Cells Determines Their Immunostimulatory Activity in a Coculture Model.Cancers · 2023Article
- Identification of novel potential genes in testicular germ cell tumors: A transcriptome analysis.Cancer biomarkers : section A of Disease markers · 2023Article
- Brain and Spinal Tumors Originating from the Germ Line Cells.Advances in experimental medicine and biology · 2023Article
- Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.Frontiers in immunology · 2023Review
- LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Platinum-based chemotherapy is usually curative for patients with testicular germ cell tumors (TGCT), but a subset of patients experience disease progression and poor clinical outcomes. Here, we tested whether immune profiling of TGCT could identify novel prognostic markers and therapeutic targets for this patient cohort. We obtained primary and metastatic TGCT samples from one center. We performed immune profiling using multiplexed fluorescence immunohistochemistry (FIHC) for T-cell subsets and immune checkpoints, and targeted gene expression profiling (Nanostring nCounter Immune panel). Publically available data sets were used to validate primary sample analyses. Nearly all samples had some degree of T-cell infiltration and immune checkpoint expression. Seminomas were associated with increased CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.